Use of abciximab for mediation of thromboembolic complications of endovascular therapy.
We describe four cases in which abciximab was used as a thrombolytic rescue agent in the setting of thrombotic events complicating interventional neuroradiologic procedures. After IV administration of abciximab, the thrombus resolved within 30 min in three cases, whereas no thrombolysis occurred in the fourth case despite the addition of intraarterial tissue plasminogen activator. Further evaluation of glycoprotein IIb-IIIa inhibitors in patients with cerebral thromboembolic events is necessary to prove clinical efficacy.
Cloft
H J
HJ
Department of Radiology, Emory University Hospital, Atlanta, GA 30322, USA.
Samuels
O B
OB
Tong
F C
FC
Dion
J E
JE
D000077284:Abciximab; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D020766:Intracranial Embolism / Q000188:drug therapy* / Q000209:etiology; D020767:Intracranial Thrombosis / Q000188:drug therapy* / Q000209:etiology; D009485:Neuroradiography / Q000009:adverse effects*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D015641:Radiography, Interventional / Q000009:adverse effects*; D015912:Thrombolytic Therapy
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab